Real life use of natalizumab, fingolimod, dimethylfumarate, teriflunomide and alemtuzumab in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

被引：0
|
作者：
Guger, M. [1 ]
Enzinger, C. [2 ]
Leutmezer, F. [3 ]
Kraus, J. [4 ]
Berger, T. [5 ]
机构：
[1] Kepler Univ Clin, Clin Neurol 2, Med Campus 3, Linz, Austria
[2] Med Univ Graz, Dept Neurol, Graz, Austria
[3] Med Univ Vienna, Dept Neurol, Vienna, Austria
[4] Publ Hosp Zell Am See, Dept Neurol, Zell Am See, Austria
[5] Med Univ Innsbruck, Dept Clin Neurol, Innsbruck, Austria
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1510
引用
收藏
页码：788 / 789
页数：2
相关论文
共 50 条
  • [1] Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 198 - 198
  • [2] Update - real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian multiple sclerosis treatment registry
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 281 - 281
  • [3] Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 315 - 316
  • [4] Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry
    Michael Guger
    Christian Enzinger
    Fritz Leutmezer
    Jörg Kraus
    Stefan Kalcher
    Erich Kvas
    Thomas Berger
    Journal of Neurology, 2019, 266 : 2678 - 2678
  • [5] Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
    Monschein, Tobias
    Dekany, Sarinah
    Zrzavy, Tobias
    Ponleitner, Markus
    Altmann, Patrick
    Bsteh, Gabriel
    Kornek, Barbara
    Rommer, Paulus
    Enzinger, Christian
    Di Pauli, Franziska
    Kraus, Jorg
    Berger, Thomas
    Leutmezer, Fritz
    Guger, Michael
    JOURNAL OF NEUROLOGY, 2023, 270 (08) : 3779 - 3786
  • [6] Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
    Tobias Monschein
    Sarinah Dekany
    Tobias Zrzavy
    Markus Ponleitner
    Patrick Altmann
    Gabriel Bsteh
    Barbara Kornek
    Paulus Rommer
    Christian Enzinger
    Franziska Di Pauli
    Jörg Kraus
    Thomas Berger
    Fritz Leutmezer
    Michael Guger
    Journal of Neurology, 2023, 270 : 3779 - 3786
  • [7] Real World Use of Natalizumab in Austria: Data from the Austrian Mulitple Sclerosis Treatment Registry (AMSTR)
    Monschein, T.
    Dekany, S.
    Bsteh, G.
    Rommer, P.
    Berger, T.
    Leutmezer, F.
    Guger, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 284 - 284
  • [8] Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry (vol 266, pg 2672, 2019)
    Guger, Michael
    Enzinger, Christian
    Leutmezer, Fritz
    Kraus, Joerg
    Kalcher, Stefan
    Kvas, Erich
    Berger, Thomas
    JOURNAL OF NEUROLOGY, 2019, 266 (11) : 2678 - 2678
  • [9] Switching natalizumab to fingolimod - real life data from Austria
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Kalcher, S.
    Kvas, E.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 307 - 308
  • [10] Efficacy and Tolerability of Fingolimod, Dimethylfumarate, and Teriflunomide in Patients with Multiple Sclerosis: Real World Experience from a Single Center
    NgocHanh Vu
    Bradshaw, Michael
    Moses, Harold
    Sriram, Subramaniam
    Pawate, Siddharama
    NEUROLOGY, 2016, 86
12345